

Adult Medication Prescription and Monitoring Record for Patients with Diabetes (Inpatient Drug Chart)

Patient Name:
Address:
Date of Birth: ADDRESSOGRAPH
NHS No:
Hospital No:

Date of Admission:	Ward	Ward Transfer	Ward Transfer	Consultant
Weight (kg):				
Height (cm)	Female patients only:		Renal function:	
BMI/BSA	Pregnant <input type="checkbox"/>		Known CKD <input type="checkbox"/>	
	Breast feeding <input type="checkbox"/>		AKI <input type="checkbox"/>	

DRUG SENSITIVITIES / ALLERGIES / ADVERSE DRUG REACTIONS - PLEASE STATE IF NO KNOWN DRUG ALLERGIES
This section must be completed before prescription/administration except in exceptional circumstances

Drug/substance	Description of allergy/reaction	Completed by (sign & designation)	Date

ONCE ONLY DRUGS (including pre-medication, loading doses and once daily gentamicin)

Please document the reason for prescribing all stat doses in the notes to aid in patient management

Date	Time	Drug	Dose	Route	Signature and contact detail	Administered			Pharmacy
						Date	Time	Initials	

Gentamicin monitoring: Take sample immediately before next due dose.
For once daily dosing trough should be <1mg/ml

Date	Date	Date
Level	Level	Level

Pharmaceutical care information

Drug history confirmed (Name, date and contact)	Nil reg meds <input type="checkbox"/>	Source of drug history: Pt PODs GP MAR Other.....
PODs brought in? Yes No	More at home? Yes No	Community pharm info
POD's checked by	Repeat prescription? Yes No	Rewritten drug chart checked (Name, date and contact)
DHx discrepancies reviewed by doctor (tick) <input type="checkbox"/> Name/bleep _____ / _____ Date _____		
Other information/comments/discrepancies (e.g. reason for drug(s) stopped or under review with reason, medication changes)		

New meds counselling	Purpose and how to take <input type="checkbox"/>	Side effects <input type="checkbox"/>	Written info, further help <input type="checkbox"/>	Inhaler counselling <input type="checkbox"/>
TTO details	Nutritional supplements on TTO RD initials/date	Yes No	TTO screened by, time and date:	Completed on ward <input type="checkbox"/> Sent to pharmacy <input type="checkbox"/>

Venous Thromboembolism (VTE) Risk Assessment for ADULT patients
(Pregnant patients; use separate Obstetrics VTE risk assessment: MVCC see below)

All adult patients must: 1) have their mobility status assessed. 2) be risk assessed, and where appropriate be prescribed appropriate thromboprophylaxis. 3) Be re-assessed appropriately during their stay as per guidance.

Step 1: MOBILITY – all patients Tick one box	Day Case Procedures considered very low risk of VTE eg Haemodialysis, Endoscopy, Chemotherapy. All local anaesthetic procedures. All regional/sedation procedures that do not involve immobilisation of lower limb <input type="checkbox"/> Risk assessment now complete Go to step 5
	SURGICAL or Medical patients acutely admitted to wards <input type="checkbox"/> Assess for thrombosis and bleeding risk Complete steps 2,3,4 and 5

Step 2: THROMBOSIS RISK (tick all that apply and score 1 for each risk factor)

Patient related risk factors	Assessment Stage				New onset (admission related) or transient risk factors	Assessment Stage			
	1	2	3	4		1	2	3	4
Active cancer or cancer treatment					Significantly reduced mobility for 3 days or more				
Age > 60					Hip or knee replacement				
Dehydration					Hip fracture				
Known thrombophilia					Surgery plus anaesthetic time > 90mins				
Personal history or first-degree relative with a history of VTE					Surgery involving pelvis or lower limb with a total anaesthetic plus surgical time > 60mins				
One or more significant medical comorbidities e.g. heart disease (acute MI within 3 months), metabolic, endocrine or respiratory pathologies; acute infectious diseases; nephrotic syndrome; active inflammatory conditions					Acute surgical admission with inflammatory or intra-abdominal condition				
Obesity (BMI >30kg/m ²)					Critical illness requiring admission to ICU/CCU/HDU				
Use of hormone replacement therapy					Surgery with significant reduction in mobility				
< 6 weeks post partum; parity >4					Mount Vernon Hospital Cancer Centre the following do not require VTE assessment or prophylaxis: 1) Ambulant patients on multiple daily chemotherapy 2) Patients on a clinical trial until clarification on day 1 post-admission 3) Patients being treated with antiangiogenic drugs e.g. sunitinib Go to step 5				
Use of oestrogen-containing contraceptive therapy									
Varicose veins with associated phlebitis									

Step 3: BLEEDING RISK (tick all that apply and score 1 for each risk factor)

Patient related risk factors	Assessment Stage				New onset (admission related) or transient risk factors	Assessment Stage			
	1	2	3	4		1	2	3	4
Active bleeding					Neurosurgery, spinal surgery or eye surgery				
Acquired bleeding disorder (such as liver failure)					Other procedures with high bleeding risk				
On therapeutic anticoagulant (e.g. dabigatran, rivaroxaban or warfarin with INR >2)					Lumbar puncture/ epidural/ spinal anaesthesia expected within the next 12 hours				
Acute stroke					Lumbar puncture/ epidural/ spinal anaesthesia within the previous 4 hours				
Thrombocytopenia (platelets <75x10 ⁹ /L)									
Uncontrolled systolic hypertension (> 230/120mmHg)									
Untreated inherited bleeding disorders (such as haemophilia or von Willebrands disease)									

CONTRAINDICATIONS to DALTEPARIN

CONTRAINDICATIONS to TEDS

Previous HIT or allergy to LMWH					Severe peripheral vascular disease; severe dermatitis/ulceration of leg; leg oedema; gross leg deformity; peripheral neuropathy; recent skin graft				
Creatinine >150micromol/L (CrCl <30ml/min): Use Dalteparin 2500 units once daily									
Urea >30mmol/L: avoid unless very high risk or monitor by antiXa assay.									

Step 4: action to be taken once risk assessed (tick which applies to patient)

Thrombosis risk score	Bleeding risk score	Intervention	Stage1 on admission	Reassessment		
				Stage 2	Stage 3	Stage 4
0	0	None needed: consider impulse or compression device or TED stockings in surgical patients				
≥ 1	0	Prescribe Dalteparin and TED stockings if appropriate				
≥ 1	≥ 1	Hold Dalteparin and review bleeding risk				

Step 5: Assessment complete

VTE risk assessed by: POA / on admission (circle)	Sign/print:	Bleep: /contact	Date:
---	--------------------	-----------------	-------

Month / Year

Patient Name:

NHS No / Hospital No:

VTE reassessment - using the tool on page 2	VTE Stage	VTE risk assessed by:		
For POA patients this should be completed on admission. Reassess all patients whenever clinical situation changes and formally as follows: Surgical patients 24 hrs post op and then every 7 days Medical patients every 7 days Obstetrics patients every 24 hrs	Stage 2	Sign/print:	Bleep:	Date:
	Stage 3	Sign/print:	Bleep:	Date:
	Stage 4	Sign/print:	Bleep:	Date:

Patient unable to receive LMWH prophylaxis (dalteparin) due to contraindication or on treatment dose of any other anticoagulant. <input type="checkbox"/>	Signature: Contact details/date
--	---

DALTEPARIN S/C PROPHYLAXIS		Date																		
Dose (circle or insert)	Start Date	18:00																		
2500 units 5000 units	Change of dose date	Standard dose: 5000 units od Renal dose: 2500 units od (Cr >150micromol/L, eGFR <30ml/min) and in patients <50kg NB Do not administer to dialysis patients on their dialysis days Pregnancy: based on patients weight - refer to Trust guidelines																		
Sign /print / contact	Pharm																			

First choice for mechanical prophylaxis is TEDS			Nursing staff – date/sign check appropriate fitting/working																	
TEDS	Sign	Date:																		
Flowtrons	Sign	Date:																		

DALTEPARIN S/C TREATMENT		Date																		
Dose (insert)	Start date	18:00																		
units	Pharm	For initial treatment of VTE see tables below (for extended treatment >30 days refer to SPC) Pregnancy and treatment of ACS refer to Trust Guidelines and prescribe in main body of chart																		
Sign/print/contact																				

Dalteparin treatment dose for VTE in patients with normal renal function					
Patient weight (Kg)	<46	46 – 56	57 – 68	69 - 82	>83
Dose (units)	7,500	10,000	12,500	15,000	18,000

Dalteparin treatment dose for VTE in patients with impaired renal function				
Patient weight (Kg)	<47	48 - 61	62 - 80	>80
eGFR 15-30 ml/min Dose (units)	5,000	6,500	8,000	10,000
eGFR <15ml/min Dose (units)	4,500	5,000	7,000	9,000

Tick box if patient receiving other parenteral anticoagulants or twice daily dalteparin
 (e.g. fondaparinux, unfractionated heparin, lepirudin, bivalirudin or danaparoid) These should be prescribed in the main body of the drug chart

ORAL ANTICOAGULANTS

Vitamin K antagonists e.g. warfarin, acenocoumarol (nicoumalone) and phenindione									
Prescribers need to ensure INR checked at appropriate intervals and dose prescribed accordingly									
Admitted on anticoagulant	<input type="checkbox"/>	Commenced this admission	<input type="checkbox"/>	Anticoagulant book with patient	<input type="checkbox"/>				
Drug		Date							
INR target		INR							
Dose on admission		Dose							
Indication	Duration	Sig							
Pharmacy	Counselled	Given by							

New oral anticoagulants e.g. dabigatran, rivaroxaban, apixaban									
Prescribers must determine whether once or twice daily dosing and circle times as appropriate.									
Admitted on anticoagulant	<input type="checkbox"/>	Commenced this admission	<input type="checkbox"/>	Alert card with patient	<input type="checkbox"/>				
Drug		Date							
Dose	Frequency (circle) Nocte bd	06:00							
Sign/print/contact		18:00							
Date	Indication	Duration	Pharmacy	Counselled	<input type="checkbox"/>				

Month / Year

Patient Name:

NHS No / Hospital No:

Codes for drugs prescribed but not administered

When a drug is not given at the appropriate time record the appropriate number on the chart. Every effort must be made to ensure medication is given as prescribed. If the reason is not readily identifiable then a record must be made in the nursing notes. In all cases if the medicine is included in the Critical Drugs List (i.e. the list of medicines that must not be omitted or delayed) the ward pharmacist should be contacted during opening hours. Outside these times contact the duty matron or night manager to arrange supply. The prescribing team may need to be informed.

- 1. Patient declined/refused
2. Patient away from ward
3. On instructions of doctor (record reason in nursing notes)
4. Medication not available
5. Patient nil by mouth: If it is a surgical patient refer to the Trust Peri-operative Policy as some drugs may need to be administered.
6. Patient nauseous and/or vomiting
7. Patient self administered (this must be under supervision, as such the nurse should also initial the box to indicate they observed the patient self administer the medication correctly)
8. Other reason. (document clearly in nursing notes)

Nursing staff: if a second check is required (e.g. all IV medicines, CDs), divide the signature box with a horizontal line to allow for two initials. Enter time administered if more than 60 minutes difference from the prescribed time.

REGULAR PRESCRIPTIONS

Table for OXYGEN prescriptions. Includes fields for Date, Time, Starting device/flow rate, PRN or Continuous, Tick here if saturations are not indicated, Sign/print/contact, Date, Drug, Start date, Route, Dose, Stop date, Additional info., Pharmacy.

Month / Year

Patient Name:

NHS No / Hospital No:

REGULAR PRESCRIPTIONS

Table for REGULAR PRESCRIPTIONS. Includes fields for Drug, Time, Date, Start date, Route, Dose, Stop date, Additional info., Sign/print/contact, Pharmacy.

ANTIMICROBIAL SECTION

Drug Allergies / Adverse Drug Reactions - State if no known drug allergies		Completed by (sign)	Date:
Drug(s):	Reaction:		

This chart is for **all treatment dose antimicrobials except once daily gentamicin** which should be prescribed on the front of this chart in the once only section. In keeping with good antimicrobial stewardship with all prescriptions you must: **State the indication** i.e. the actual or presumed source of infection.

Prescribe in line with approved Trust Guidelines or after consultation with a Consultant Microbiologist and/or in light of relevant cultures and sensitivities. The rationale for the choice of agent should be documented in the medical notes and indicated on the prescription (including prophylactic regimens).

Antimicrobial therapy should be reviewed daily but formally around 48 hours and 5 days signing and dating the review boxes. Consider IV to oral switch and de-escalation as and when appropriate (re-writing any oral agent using a new prescription box). If the antimicrobials are to continue beyond 7 days you must record in the medical notes the rationale and then endorse the prescription in the box provided. Where no documentation or endorsement exists treatment will be stopped in line with the Antimicrobial Stop Policy. If the review boxes are likely to correspond to weekend or bank holidays please review in advance to ensure no unintentional interruption to treatment.

Note: The day of treatment (Day of Tx) box indicates the total duration of antimicrobial use since the initial prescription.

Drug		Dose	Route	Date →							To continue ≥ 7 days you MUST document indication here
				Day of Tx							
Start date	Indication	Per guidelines <input type="checkbox"/>	Micro approved <input type="checkbox"/>	02:00							
Signature / Print Bleep/contact		Estimated stop date:		06:00							
Reviewed at 48 hrs Sign	Date	Additional information		10:00							
Reviewed at 5 days Sign	Date	Pharmacy		12:00							
				14:00							
Start date	Indication	Per guidelines <input type="checkbox"/>	Micro approved <input type="checkbox"/>	02:00							
Signature / Print Bleep/contact		Estimated stop date:		06:00							
Reviewed at 48 hrs Sign	Date	Additional information		10:00							
Reviewed at 5 days Sign	Date	Pharmacy		12:00							
				14:00							
Start date	Indication	Per guidelines <input type="checkbox"/>	Micro approved <input type="checkbox"/>	02:00							
Signature / Print Bleep/contact		Estimated stop date:		06:00							
Reviewed at 48 hrs Sign	Date	Additional information		10:00							
Reviewed at 5 days Sign	Date	Pharmacy		12:00							
				14:00							
Start date	Indication	Per guidelines <input type="checkbox"/>	Micro approved <input type="checkbox"/>	02:00							
Signature / Print Bleep/contact		Estimated stop date:		06:00							
Reviewed at 48 hrs Sign	Date	Additional information		10:00							
Reviewed at 5 days Sign	Date	Pharmacy		12:00							
				14:00							

AS REQUIRED PRESCRIPTIONS

Sodium chloride 0.9%		5 – 20ml	Date																
IV flush		As needed	Time																
Start date	Pre and post injection/infusions and to maintain line patency		Dose																
Sign/print/contact		Pharmacy	Route																
Drug		Dose	Given by																
			Date																
			Time																
Route	Max frequency		Dose																
Start date	Indication		Route																
Sign/print/contact		Pharmacy	Given by																
Drug		Dose	Date																
			Time																
Route	Max frequency		Dose																
Start date	Indication		Route																
Sign/print/contact		Pharmacy	Given by																
Drug		Dose	Date																
			Time																
Route	Max frequency		Dose																
Start date	Indication		Route																
Sign/print/contact		Pharmacy	Given by																
Drug		Dose	Date																
			Time																
Route	Max frequency		Dose																
Start date	Indication		Route																
Sign/print/contact		Pharmacy	Given by																
Drug		Dose	Date																
			Time																
Route	Max frequency		Dose																
Start date	Indication		Route																
Sign/print/contact		Pharmacy	Given by																

Prescribe initial dose in first column. If any dose changes are required DELETE THE WHOLE PREVIOUS COLUMN and rewrite doses for ALL insulin used in dose change columns

Insulin: exact type/brand (no abbreviations)	Initial Dose	Dose change 1		Dose change 2		Dose change 3		Dose change 4		NURSES – Record dose administered and time below If the patient self administers this must be observed under supervision Always use an insulin syringe or a standard insulin device														
		Type	Units	Sign Date	Units	Sign Date	Units	Sign Date	Units	Sign Date	Date	Dose	Units	Time	Sign	Dose	Units	Time	Sign	Dose	Units	Time	Sign	
Breakfast		Type	Units	Sign Date	Units	Sign Date	Units	Sign Date	Units	Sign Date														
Lunch		Type	Units	Sign Date	Units	Sign Date	Units	Sign Date	Units	Sign Date														
Evening meal		Type	Units	Sign Date	Units	Sign Date	Units	Sign Date	Units	Sign Date														
Bed		Type	Units	Sign Date	Units	Sign Date	Units	Sign Date	Units	Sign Date														
Pharmacy check/ comments												Supply details												

Blood Glucose Monitoring Chart

Month / Year

Patient Name:

NHS No / Hospital No:

Date	Time	Glucose	Breakfast				Lunch				Evening Meal				Bed			
			Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post		
>22 record value																		
21																		
20																		
19																		
18																		
17																		
16																		
15																		
14																		
13																		
12																		
11																		
10																		
9																		
8																		
7																		
6																		
5																		
4																		
<3.9 record value																		

>19	Refer to medical/diabetes team
11.1 - 18.9	Review and consider referral to medical team
4-11	Continue Monitoring
<3.9	Follow Trust Hypoglycaemia Guideline and refer to medical/diabetes team

Date		Treatment		Date		Glucose		Treatment		Date		Glucose		Treatment	
Time		Time		Time		Time		Time		Time		Time		Time	

Record high frequency glucose readings taken during the treatment of hypoglycaemia (every 15mins as per guideline)

Blood Glucose Monitoring Chart

Month / Year

Patient Name:

NHS No / Hospital No:

Date	Breakfast				Lunch				Evening Meal				Bed			
	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
Time																
Glucose																
>22 record value																
21																
20																
19																
18																
17																
16																
15																
14																
13																
12																
11																
10																
9																
8																
7																
6																
5																
4																
<3.9 record value																

>19	Refer to medical/diabetes team
11.1 - 18.9	Review and consider referral to medical team
4-11	Continue Monitoring
<3.9	Follow Trust Hypoglycaemia Guideline and refer to medical/diabetes team

Record high frequency glucose readings taken during the treatment of hypoglycaemia (every 15mins as per guideline)

Date	Breakfast		Lunch		Evening Meal		Bed	
	Pre	Post	Pre	Post	Pre	Post	Pre	Post
Time								
Treatment								
Glucose								
Time								
Treatment								
Glucose								
Time								
Treatment								
Glucose								

Variable Rate Intravenous Insulin Infusion (VRIII) Prescription Chart

Patient name: _____

Hospital No _____

1. Prescribe Insulin for Infusion

Nurses : Always use an insulin syringe to draw up insulin

Date	Intravenous fluid	Volume	Additive drug	Prescribers signature	Prescriber Bleep/contact	Time started	Time stopped	Serial/Batch No of insulin	Nursing signature	Nursing signature
	Sodium Chloride 0.9%	49.5 ml	Human Actrapid 50 units							
	Sodium Chloride 0.9%	49.5 ml	Human Actrapid 50 units							
	Sodium Chloride 0.9%	49.5 ml	Human Actrapid 50 units							
	Sodium Chloride 0.9%	49.5 ml	Human Actrapid 50 units							

2. Prescribe insulin rates to be used

DOCTORS: If you wish to change the scale used, cross out the scale no longer required, and sign the new scale.	Scale 1 Standard		Scale 2 If not achieving target or BMI 35 kg /m ²		Scale 3 Customised	
	Glucose	Insulin Rate Units/hour	Glucose	Insulin Rate Units/hour	Glucose	Insulin Rate Units/hour
NURSES: Check blood glucose every hour.	<4	0.5 Follow hypo guideline	<4	0.5 Follow hypo guideline		
	4.1-7.0	1	4.1-7.0	2		
	7.1-9.0	2	7.1-9.0	3		
	9.1-11.0	3	9.1-11.0	4		
	11.1-14.0	4	11.1-14.0	5		
	14.1-17.0	5	14.1-17.0	6		
	17.1-19	6	17.1-19	7		
>19	Seek Diabetes/medical attention	>19	Seek Diabetes/medical attention			
Date/Time						
Signature						

Scale 1 Standard

Scale 2 If not achieving target or BMI 35 kg /m²

Scale 3 Customised

Guidance

Scale 1. Use this scale initially. Review after 4 hours and change to scale 2 if targets not achieved. If need to go back-again to scale 1 – rewrite using customised scale columns. Use a new chart if there are no spaces left.

Scale 2. Start on this scale in patients with Type 2 diabetes with a BMI >35kg/m².

Scale 3. Customised scale for use if previous scales not achieving targets. Seek advice from the diabetes team.

For DKA use the ICP provided with the Adult DKA Guidance.

NB. 16yr and 17yr old patients must use Paediatric DKA Guidance

HHS and ACS - See trust Guideline for the management of these conditions and prescribe in Customised Scale 3.

Remember

1. If the patient usually takes basal insulin (e.g levemir/ glargine) this must be continued even whilst on VRIII
2. When discontinuing VRIII, give the next subcutaneous insulin dose due then stop IV insulin 30 minutes LATER
3. Prescribe accompanying fluids
4. Intercurrent illness often increases insulin requirements

